ADC Therapeutics SA (ADCT)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
ADCT Insider Trading Activity
ADCT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $2,857,000 | 2 | 18 |
Sells | $278,289 | 9 | 82 |
Related Transactions
| Redmile Group, LLC | 10 percent owner | 2 | $2.86M | 1 | $52,479 | $2.8M |
| Hug Peter | director | 0 | $0 | 1 | $3,448 | $-3,448 |
| Monges Viviane | director | 0 | $0 | 1 | $4,153 | $-4,153 |
| Pfisterer Thomas | director | 0 | $0 | 1 | $4,153 | $-4,153 |
| Azelby Robert | director | 0 | $0 | 1 | $20,216 | $-20,216 |
| BIZZARI JEAN-PIERRE | director | 0 | $0 | 1 | $20,216 | $-20,216 |
| Sandor Victor | director | 0 | $0 | 1 | $20,216 | $-20,216 |
| Squarer Ron | director | 0 | $0 | 1 | $20,216 | $-20,216 |
| MALLIK AMEET | Chief Executive Officer | 0 | $0 | 1 | $133,195 | $-133,195 |
About ADC Therapeutics SA
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or …
Insider Activity of ADC Therapeutics SA
Over the last 12 months, insiders at ADC Therapeutics SA have bought $2.86M and sold $278,289 worth of ADC Therapeutics SA stock.
On average, over the past 5 years, insiders at ADC Therapeutics SA have bought $2.86M and sold $278,289 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Redmile Group, LLC (10 percent owner) — $2.86M.
The last purchase of 200,000 shares for transaction amount of $609,000 was made by Redmile Group, LLC (10 percent owner) on 2024‑12‑11.
List of Insider Buy and Sell Transactions, ADC Therapeutics SA
| 2024-12-11 | Redmile Group, LLC | 10 percent owner | 200,000 0.2806% | $3.04 | $609,000 | -20.95% | ||
| 2024-12-04 | Sale | Redmile Group, LLC | 10 percent owner | 25,352 0.0263% | $2.07 | $52,479 | -14.73% | |
| 2024-07-01 | Redmile Group, LLC | 10 percent owner | 800,000 0.9607% | $2.81 | $2.25M | -24.18% | ||
| 2024-06-17 | Sale | Pfisterer Thomas | director | 1,437 0.0018% | $2.89 | $4,153 | -1.95% | |
| 2024-06-17 | Sale | Hug Peter | director | 1,193 0.0015% | $2.89 | $3,448 | -1.95% | |
| 2024-06-17 | Sale | Monges Viviane | director | 1,437 0.0018% | $2.89 | $4,153 | -1.95% | |
| 2024-06-17 | Sale | Sandor Victor | director | 6,995 0.0086% | $2.89 | $20,216 | -1.95% | |
| 2024-06-17 | Sale | Squarer Ron | director | 6,995 0.0086% | $2.89 | $20,216 | -1.95% | |
| 2024-06-17 | Sale | BIZZARI JEAN-PIERRE | director | 6,995 0.0086% | $2.89 | $20,216 | -1.95% | |
| 2024-06-17 | Sale | Azelby Robert | director | 6,995 0.0086% | $2.89 | $20,216 | -1.95% | |
| 2024-05-07 | Sale | MALLIK AMEET | Chief Executive Officer | 29,731 0.0569% | $4.48 | $133,195 | -40.58% | |
| 2009-03-06 | FORET MICKEY P | director | 10,000 0.0118% | $2.75 | $27,500 | |||
| 2007-06-20 | Sale | SWITZ ROBERT E | PRES & CEO | 8,000 0.065% | $19.02 | $152,160 | ||
| 2006-06-20 | Rehfeld John E | director | 1,000 0.0069% | $16.14 | $16,135 | |||
| 2006-06-07 | FORET MICKEY P | director | 10,000 0.0746% | $17.46 | $174,600 | |||
| 2006-06-07 | MARTIN LOIS M | director | 1,000 0.0075% | $17.46 | $17,460 | |||
| 2006-06-05 | BLANCHARD JOHN A III | director | 15,000 0.1136% | $17.72 | $265,856 | |||
| 2004-01-16 | Sale | JOHNSON B KRISTINE | director | 16,000 0.0251% | $3.67 | $58,720 |
ADCT Institutional Investors: Active Positions
| Increased Positions | 49 | +72.06% | 7M | +13.61% |
| Decreased Positions | 25 | -36.76% | 6M | -10.66% |
| New Positions | 16 | New | 3M | New |
| Sold Out Positions | 11 | Sold Out | 4M | Sold Out |
| Total Postitions | 92 | +35.29% | 56M | +2.95% |
ADCT Ownership Change vs Market
Institutional Investor Ownership
| Redmile Group, Llc | $28,983.00 | 16.15% | 15.67M | -2,486 | -0.02% | 2024-12-31 |
| Prosight Management, Lp | $17,603.00 | 9.81% | 9.52M | -121,237 | -1.26% | 2024-12-31 |
| Orbimed Advisors Llc | $11,042.00 | 6.15% | 5.97M | +1M | +31.64% | 2024-12-31 |
| Blackrock, Inc. | $9,272.00 | 5.17% | 5.01M | +612,723 | +13.93% | 2024-12-31 |
| Morgan Stanley | $7,319.00 | 4.08% | 3.96M | +915,378 | +30.1% | 2024-12-31 |
| Woodline Partners Lp | $3,577.00 | 1.99% | 1.93M | +2M | New | 2024-12-31 |
| Goldman Sachs Group Inc | $3,095.00 | 1.73% | 1.67M | -15,417 | -0.91% | 2024-12-31 |
| Platinum Investment Management Ltd | $2,983.00 | 1.66% | 1.61M | +168,040 | +11.63% | 2024-12-31 |
| Bank Of America Corp /De/ | $2,389.00 | 1.33% | 1.29M | -1M | -48.31% | 2024-12-31 |
| State Street Corp | $2,198.00 | 1.23% | 1.19M | +82,183 | +7.43% | 2024-12-31 |